Histamine dihydrochloride
Ceplene (histamine dihydrochloride) is a small molecule pharmaceutical. Histamine dihydrochloride was first approved as Histamine phosphate on 1982-01-01. It is used to treat allergic rhinitis seasonal and urticaria in the USA. It has been approved in Europe to treat myeloid leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 2nd chance mobility pain relief | C200263 | 2024-01-08 |
| activon ultra strength arthritis | OTC monograph not final | 2015-04-22 |
| alo therapeutic massage | C200263 | 2023-11-10 |
| alo therapeutic massage pain relieving | C200263 | 2023-11-10 |
| amino active topical analgesic cream | C200263 | 2023-11-11 |
| arthritis pain relief | C200263 | 2024-12-11 |
| arthritis pain relief cream | OTC monograph not final | 2019-12-09 |
| australian dream back pain | C200263 | 2024-01-18 |
| back pain cream | OTC monograph not final | 2019-12-09 |
| bakers best arthritis pain relief | C200263 | 2023-11-11 |
Show 14 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1559 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Weight gain | D015430 | — | — | — | — | — | 1 | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Histamine dihydrochloride |
| INN | — |
| Description | Histamine dihydrochloride (INN, trade name Ceplene) is a salt of histamine that is used as a drug for the prevention of relapse in patients diagnosed with acute myeloid leukemia (AML).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cl.Cl.NCCc1c[nH]cn1 |
Identifiers
| PDB | — |
| CAS-ID | 56-92-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1533310 |
| ChEBI ID | — |
| PubChem CID | 5818 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,003 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use